Literature DB >> 28032069

TB/HIV Co-infection in Iran: Current Situation and the Modeling Study for Future Policy.

Shahab Rezaeian1, Somayeh Khazaei2, Salman Khazaei3.   

Abstract

Entities:  

Year:  2016        PMID: 28032069      PMCID: PMC5182266     

Source DB:  PubMed          Journal:  Iran J Public Health        ISSN: 2251-6085            Impact factor:   1.429


× No keyword cloud information.

Dear Editor-in-Chief

Tuberculosis (TB) is the commonest opportunistic disease among HIV patients with an estimated of 1.2 million HIV positive new TB cases in the world, in 2014 (1, 2). TB is the leading cause of death among HIV/AIDS patients (2) and it also enhances the progression of HIV to AIDS, increases the infectivity and reduces the efficacy of HIV treatment (3). Up to 10% of HIV/TB patients develop active TB (4). Co-infection with HIV can enhance the risk of latent TB reactivation by 20-fold (5). According the projection of WHO, TB and HIV infections will one of the tops 20 causes of death in 2030 (6). Based on the WHO report, the status of HIV morbidity in 29% of Iranian TB patients were clear and 9% of them were HIV positive (Table 1). The estimated incidence rate of TB in Iran was 22 (18–26) and among TB/HIV cases was 0.51 (0.38 – 0.66) per 100,000 persons in 2014 (Table 2) (7).
Table 1:

Status of TB/HIV co-morbidity in Iran based on TB case notifications, 2014

TB/HIV statusNumberPercent
TB patients with known HIV status300929
HIV-positive TB patients2729
HIV-positive TB patients on antiretroviral therapy (ART)10037
HIV-positive people screened for TB8233
Table 2:

Estimates of TB burden in Iran, 2014

Estimates of TB burdenNumber (thousands)Rate (per 100,000 population)
Mortality (excludes HIV+TB)2.7(1.9 – 3.7)3.5(2.4 – 4.7)
Mortality (HIV+TB only)0.11(0.07– 0.15)0.14(0.09 – 0.19)
Prevalence (includes HIV+TB)26(13 – 43)33(17 – 55)
Incidence (includes HIV+TB)17(14 – 20)22(18 – 26)
Incidence (HIV+TB only)0.4(0.3 – 0.52)0.51(0.38 – 0.66)
Status of TB/HIV co-morbidity in Iran based on TB case notifications, 2014 Estimates of TB burden in Iran, 2014 The dynamics of the TB epidemic depends on the HIV status in a country. Therefore is necessary to control TB in high HIV prevalence sub-populations to achieve the high rates of detection and successful treatment of TB cases. In other words, additional measures are also necessary to develop improved specific TB control. The modelling studies have provided (8, 9) the significant data on the epidemiology of TB, which might be useful on future policies and interventions for TB control in Iran.
  6 in total

1.  Planning to improve global health: the next decade of tuberculosis control.

Authors:  Dermot Maher; Chris Dye; Katherine Floyd; Andrea Pantoja; Knut Lonnroth; Alasdair Reid; Eva Nathanson; Thad Pennas; Uli Fruth; Jane Cunningham; Heather Ignatius; Mario C Raviglione; Irene Koek; Marcos Espinal
Journal:  Bull World Health Organ       Date:  2007-05       Impact factor: 9.408

Review 2.  HIV-associated tuberculosis: clinical update.

Authors:  Soumya Swaminathan; C Padmapriyadarsini; G Narendran
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

3.  Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy.

Authors:  Weerawat Manosuthi; Suthat Chottanapand; Supeda Thongyen; Achara Chaovavanich; Somnuek Sungkanuparph
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

Review 4.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.

Authors:  Elizabeth L Corbett; Catherine J Watt; Neff Walker; Dermot Maher; Brian G Williams; Mario C Raviglione; Christopher Dye
Journal:  Arch Intern Med       Date:  2003-05-12

5.  Tuberculosis: current situation, challenges and overview of its control programs in India.

Authors:  Gursimrat K Sandhu
Journal:  J Glob Infect Dis       Date:  2011-04

6.  Tuberculosis control in China: use of modelling to develop targets and policies.

Authors:  Hsien-Ho Lin; Lixia Wang; Hui Zhang; Yunzhou Ruan; Daniel P Chin; Christopher Dye
Journal:  Bull World Health Organ       Date:  2015-09-15       Impact factor: 9.408

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.